

SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Diabetes Mellitus Type 2 High Cardiovascular Risk

Pharmaceutical Services

Department of Health and Community Services P.O. Box 8700, Confederation Bldg.

St. John's, NL A1B 4J6

Phone: Toll Free Line: Fax:

(709) 729-6507 1-888-222-0533 (709) 729-2851

	Patient Information
Pa	tient Name Date of Birth NLPDP Drug Card/MCP Number
Ad	ldress
REQUESTED DRUG NAME and DIAGNOSTIC INFORMATION	
□,	Jardiance (empagliflozin): DM Type 2 High Cardiovascular Risk
pa	s an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular death in tients with type 2 diabetes mellitus and established cardiovascular disease who have inadequate glycemic ontrol despite an adequate trial of metformin.
	Inadequate control on metformin: Dose/Duration:
PΙ	ease provide details of cardiac risk below:
	History of myocardial infarction (MI)
	Multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)
	Single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection
	Last episode of unstable angina >2 months prior with confirmed evidence of coronary multi/single vessel disease
	History of ischemic or hemorrhagic stroke
	Occlusive peripheral artery disease
	Synjardy (empagliflozin/metformin)
For the treatment of type 2 diabetes mellitus in patients who are already stabilized on therapy with empagliflozin and metformin.	
En	mpaglifozin dose: Metformin dose:
Patients must meet coverage criteria for empagliflozin. Please complete relevant form if patient does not already have NLPDP coverage for empagliflozin.	
Pr	rescriber Information / Requested By:
Prescriber Name: please print)	
Ad	Idress: License Number:
Sig	gnature: Fax Number: Fax Number: